The private sector holds many of the assets and data needed for efficient drug repurposing. However, because innovative ideas for new uses of these resources can come from a variety of organizations, including NIH and the broader biomedical research community, public-private partnerships and collaborations are critical to this research. Through the New Therapeutic Uses program’s NIH–Industry Partnerships initiative, pharmaceutical companies provide researchers with access to the partially developed therapeutic candidates (referred to as assets) and related data.
These assets have undergone significant pre-clinical and safety testing in humans and are ready for additional testing in patient populations. Making information about these promising assets available to the research community gives scientists an opportunity to explore potential new therapeutic uses in previously unexplored disease areas. The collaborating pharmaceutical companies have identified assets suitable for adult indications as well as for pediatric indications.